Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2006-11-21
2006-11-21
Nashed, Nashaat T. (Department: 1656)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S094630, C424S094600, C435S219000
Reexamination Certificate
active
07138114
ABSTRACT:
Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the lyophilized composition, and a kit and method for reconstituting the lyophilized composition are described herein.
REFERENCES:
patent: 4083961 (1978-04-01), Dussourdd'Hinterland et al.
patent: 4447236 (1984-05-01), Quinn
patent: 4610879 (1986-09-01), Markland et al.
patent: 4692139 (1987-09-01), Stiles
patent: 4755167 (1988-07-01), Thistle et al.
patent: 4812405 (1989-03-01), Lair et al.
patent: 4818700 (1989-04-01), Cregg et al.
patent: 4837148 (1989-06-01), Cregg
patent: 4855231 (1989-08-01), Stroman et al.
patent: 4885242 (1989-12-01), Cregg
patent: 5167628 (1992-12-01), Boyles
patent: 5222941 (1993-06-01), Don Michael
patent: 5250034 (1993-10-01), Appling et al.
patent: 5370653 (1994-12-01), Cragg
patent: 5380273 (1995-01-01), Dubrul et al.
patent: 5498236 (1996-03-01), Dubrul et al.
patent: 5626564 (1997-05-01), Zhan et al.
patent: 5709676 (1998-01-01), Alt
patent: 5830468 (1998-11-01), Bini
patent: 5865178 (1999-02-01), Yock
patent: 5922322 (1999-07-01), Bini
patent: 5951981 (1999-09-01), Markland, Jr. et al.
patent: 6020181 (2000-02-01), Bini
patent: 6107280 (2000-08-01), White et al.
patent: 6455269 (2002-09-01), Toombs
patent: 6759431 (2004-07-01), Hunter et al.
patent: 2002/0081685 (2002-06-01), Fox et al.
patent: 0 323 722 (1989-07-01), None
patent: 03 23 722 (1989-07-01), None
patent: 0 438 200 (1991-07-01), None
patent: 0 624 642 (1994-11-01), None
patent: 0 689 843 (1996-01-01), None
patent: WO 90/07352 (1990-07-01), None
patent: WO 96/36227 (1996-11-01), None
patent: WO 98/24917 (1998-06-01), None
patent: WO 98/46771 (1998-10-01), None
patent: WO 01/24817 (2001-04-01), None
patent: WO 01/25445 (2001-04-01), None
patent: WO 02/12283 (2002-02-01), None
Pretzer et al. “Stability of the thrombolytic protein fibrolase: . . . ” Pharm. Res. 1991, 8 (9), 1103-1112.
Carpenter et al. “Interaction of stabilizing additives with proteins during freeze-thawing and freeze-drying” Develop. Biol. Standard 1991, 74, pp. 225-239.
Williams et al. “The lyophilization of pharmaceuticals: A literature review” J. Parenteral Sci. Tech. 1984, 38 (2), 4859.
Williams et al., Journal of Parenteral Science and Technology, vol. 38, pp. 48-59 (1984).
Chen, Drug Development and Industrial Pharmacy, vol. 18, No. 11 and 12, pp. 1311-1354 (1992).
Carpenter et al., Developments in Biological Standardization, vol. 74, pp. 225-239 (1991).
Guan et al., Archives of Biochemistry and Biophysics, vol. 289, No. 2. pp. 197-207 (1991).
Randolph et al., Protein Science, Cambridge University Press (1992), pp. 590-600.
Markland et al., Circulation, vol. 90, No. 5, pp. 2448-2456 (1994).
Loayza et al., Journal of Chromatography B. pp. 227-243 (1994).
[No authors listed],Annals of Surgery, 220(3):251-266 (1994).
Ahmed et al.,Haemostasis, 20:147-154 (1990).
Ahmed, N.K. “Biological and Thrombolytic Properties of Fibrolase,”Haemostasis, 20:334-340 (1990).
Barrett, A.J. (ed.),Methods in Enzymology, Academic Press, Inc., Philadelphia, PA, pp. 737-754 (1981).
Jackson and Clagett,Chest, 114:666S-682S (1998).
Manning, “Sequence Analysis of Fibrilase, a Fibrinolytic Metalloroteinase fromAgkistrodon Contortrix Contortrix,” Toxicon, 33(9):1189-1200 (1995).
Markland et al., “Resolution of Isoforms of Natural and Recombinant Fibrinolytic Snake Venom Enzyme Using High Performance Capillary Electrophoresis,”Journal of Liquid Chromatography 16(1-10): 2189-2201 (1993).
Ouriel et al.,Journal of Vascular Surgery, 19:1021-1030 (1994).
Ouriel et al.,New England Journal of Medicine, 338:1105-1111 (1998).
Pretzer et al.,Pharmaceutical Research, 9(7):870-877 (1992).
Retzios et al.,Thrombosis Research, 74(4):355-367 (1994).
Rholam et al., “Role of amino acid sequences flanking dibasic cleavage sites in precursor proteolytic processing-The importance of the first residue C-terminal of the cleavage site,”European Journal of Biochemistry 227:707-714 (1995).
Sreekrishna et al., “Strategies for optimal sysnthesis and secretion of heterologous proteins in the methylotrophic yeastPichis pastoris,” Gene 190:55-62 (1997).
Kandarpa et al., “Forceful Pulsatile Local Infusion of Enzyme Accelerates Thrombolysis: In Vivo Evaluation of a New Delivery System,”Radiology, 168:739-744 (1981).
Potempa et al., “Stabilization vs. degradation ofStaphylococcus aureusmetalloproteinase,”Biochimica et Biophysica Acia, 993:301-304 (1989).
Carpenter et al., Developments in Biological Standardization, 74:225-239 (1991).
Chen et al., Drug Development and Industrial Pharmacy, 15:1311-1354 (1992).
Guan et al., Archives of Biochemsitry and Biophysics, 289:197-207 (1991).
Loayza et al., Journal of Chromatography B, 227-243 (1994).
Markland et al., Circulation, 90:2448-2456 (1994).
Randolph et al., Protein Science, Cambridge University Press, pp. 590-600 (1992).
Williams et al., Journal of Parenteral Science and Technology, 38:48-59 (1984).
Anai et al., “Inhibition of a Snake Venom Hemorrhagic Metalloproteinase by Human and Rat Alpha-Macroglobulins,” Toxicon: Official Journal of the International Society on Toxinology, 36(8):1127-1139 (1998).
Bode et al., Astacins, Serralysins, Snake Venom and Matrix Metalloproteinases Exhibit Identical Zinc-Binding Environments (HEXXHXXGXXH and Met-Turn) and Topologies and Should be Grouped Into a Common Family, The ‘Metzincins’, FEBS Lett., 331(1-2):134-140 (1993).
Stocker et al., “The Metzincins-Topological and Sequential Relations Between the Astacins, Adamalysins, Serralysins, and Matrixins (Collagenases Define a Superfamily of Zinc-Peptidases,” Protein Sci., 4(5):823-840 (1995).
Verstraete et al., “Thrombolytic Agents in Development,” Drugs, 50(1):29-42 (1995).
Selistre de Araujo et al., “Molecular Cloning and Sequence Analysis of CDNAS for Metalloproteinases From Broad-Banded Copperhead Agkistrodon Contortrix Laticinctus”, Archives of Biochemistry and Biophysics 320(1):141-148 (1995).
Kendrick Brent S.
Peterson Brian A.
Amgen Inc.
Nashed Nashaat T.
Robins & Pasternak LLP
LandOfFree
Pharmaceutical compositions of fibrinolytic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions of fibrinolytic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions of fibrinolytic agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3701755